Interestingly, CXCR2 is an important biomarker of neuroendocrine prostate cancer (NEPC), and our strategy is also beneficial for drug-resistant PCa therapy, as it significantly suppresses the progression of NEPC 24. The gene discussed is CXCR2; the disease is posterior cortical atrophy.